Effects of Finerenone on Renal Hemodynamics and Oxidative Stress

Non-traditional risk factors such as oxidative stress and inflammation are highly prevalent in patients with chronic kidney disease, cardiovascular disease and diabetes mellitus. Diabetes mellitus, which is considered at the beginning as a metabolic disorder, converts rapidly into a predominantly vascular disease. Hyperglycemia upregulates markers of chronic inflammation and contribute to increased reactive oxygen species generation, which ultimately cause vascular dysfunction. Endothelial dysfunction occurs early in the process of vascular impairment. One of the potential mechanisms contributing to endothelial dysfunction in diabetic patients is inactivation of nitric oxide by oxygen-derived free radicals. Similarly, oxidatively mediated degradation of endothelium-derived nitric oxide contributing to abnormal endothelium-dependent vasodilation has been observed in animal models of diabetes mellitus. Similar mechanisms are associated with early chronic kidney disease and its progression. Indeed, studies in animal models have demonstrated that administration of antioxidants restores normal endothelial function.

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo (FIDELIO, FIGARO studies and FIDELITY analysis). Preclinical data showed that the kidney and cardiovascular benefits of finerenone were associated with potent anti-inflammatory and antifibrotic effects through inhibition of overactivation of the mineralocorticoid receptor. Blockade of the mineralocorticoid receptor with finerenone may reduce production of reactive oxygen species, observed to be increased in diabetes already at the early stage as well as in patients with overt nephropathy. However, there is no study in humans supporting this mechanism how finerenone may exert nephroprotective effects. This mechanistic study attempts to support this concept with in vivo data in patients.

Vitamin C is a water-soluble antioxidant capable of scavenging free radicals and was found to restore the impaired endothelium-dependent vasodilation in the forearm resistance vessels of patients with diabetes mellitus. The investigators previously examined the role of oxidative stress in the renal circulation in humans by measuring the response of Vitamin C on renal plasma flow with constant clearance input technique. The investigators observed first that vitamin C reduced the high level of oxidative stress in the renal vasculature in smokers known to have increased oxidative stress. Subsequently, the investigators found in patients with type 2 diabetes with normal renal function that the increase of renal plasma flow following vitamin C infusion is augmented in type 2 diabetes indicating increased formation of reactive oxygen species already in the early stage of diabetic disease. Finally, the investigators also found infusion of the antioxidant vitamin C (on top of L-arginine) induced a more pronounced increase in renal plasma flow in patients with chronic kidney disease than in control subjects. All these previous studies allowed us to conclude that vitamin C infusion is a tool to measure oxidative stress of the renal vasculature in humans in vivo, which clearly contrasts the measurement of biomarkers in the urine or peripheral blood samples. In addition, the infusion of L-arginine, a substrate for nitric oxide synthesis, emerged in our hands as a tool to measure nitric oxide synthesis in the renal circulation, since the vasodilatory response to L-arginine, at least in part, was due to increased production and release of nitric oxide. Thus, the bioavailability of nitric oxide can be judged by measuring the change of renal plasma flow to L-arginine infusion in addition to measure albuminuria.

Patients with type 2 diabetes are an ideal study population to analyze any effect of an intervention on oxidative stress and nitric oxide bioactivity since hyperglycemia upregulates markers of chronic inflammation and contributes to increased reactive oxygen species already in the prediabetes stage, far before renal function or cardiovascular atherosclerotic processes become clinically overt. Our data in patients with type 2 diabetes who had normal renal function support this notion. Effects of finerenone on oxidative stress are therefore measurable in this early stage of type 2 diabetes. Furthermore, our so far used model of measuring oxidative stress (by vitamin C infusion) and stimulated nitric oxide bioactivity (by L-arginine infusion) in the renal circulation has been validated for eGFR >45 ml/min/1.73m² and our findings were consistently found in type 2 diabetes as well as in patients with diagnosed chronic kidney disease.

The investigators use the constant input clearance technique, considered globally as gold standard to analyze renal function, with para-amino-hippuric acid (PAH) for the measurement of renal plasma flow and iohexol (inulin and sinestrin are no longer available) for the measurement of glomerular filtration rate. The investigators therefore avoid any inaccuracy related to incomplete urine sampling and complete bladder voiding. In addition, the investigators apply the Gomez formula to estimate intraglomerular pressure and afferent and efferent glomerular resistances. This is possible if the Gomez formula are applied to measurements in patients with only minor altered renal morphology (i.e normal renal function). To our knowledge, no detailed analysis of renal hemodynamics, including intraglomerular resistances, are available for finerenone in humans. A decrease of the intraglomerular pressure could be an additional explanation of the beneficial nephroprotective effects of finerenone. Please note that the investigators have used this technique as part of several studies and clinics (for example to analyze the exact renal function in potential kidney donors) since more than 20 years.